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Abstract. The importance of metabolic syndrome (MetSy) lies in the fact that its components are proven risk factors for 
early blood vessel atherosclerosis and thrombosis.Aim of the paper: Our aim was to establish the prevalence of MetSy in 
patients with arterial hypertension (AH) and its impact on asymptomatic carotid atherosclerosis. The study involved 391 
examinees, divided into two groups. The study group consisted of patients with arterial hypertension (n=342; average age, 
66.56 ± 09.52; with 51% of female gender). The presence of cardiovascular (CV) risk factors was established for all 
involved patients, cardiovascular risk score was determined (SCORE risk), laboratory analyses were performed, as well as 
anthropometric measurements and color Doppler sonography of the great blood vessels of the neck. The patients with AH 
were divided into two groups according to the presence of MetSy. Metabolic syndrome was confirmed in 198 patients who 
comprised group I; there were 144 examinees without MetSy and these comprised group II. Those with MetSy had a greater 
average number of CV risk factors, a higher SCORE risk score, higher body mass index (p<0.0001), and more frequently 
had diabetes, hyperlipidemia and obesity. The thickness of the intimal medial complex (IMC) of the carotid arteries was 
significantly greater in the group with MetSy (p<0.0001) – 51% of examinees had IMC thickness ≥0.90. The patients with 
MetSy more commonly had one or more carotid plaques (p=0.03), a higher average number of plaques (p=0.01) and 
percentage of stenosis (p=0.01). As the most important factors associated with early carotid atherosclerosis, multivariant 
regression analysis singled out the following (for the model R=0.512. R2=0.262. adjusted R2=0.255. standard error of the 
estimate = 0.174; p<0.0001): age (coefficiant β=0.331. p<0.0001), number of MetSy components (coefficient β=0.158. 
p=0.002), level of serum uric acid (coefficient β=0.284; p<0.0001). Our results demonstrated a significant association of 
MetSy and its components with early atherosclerotic changes in the carotid arteries. 
Key words: metabolic syndrome,  arterial hypertension,  asymptomatic carotid atherosclerosis, carotid intima-media 
thickness, carotid plaque. 
Introduction

 
Metabolic syndrome (MetSy) represents a group of car-
diovascular risk factors, such as obesity, hypertension, 
insulin resistance and dyslipidemia. The importance of 
MetSy lies in the fact that its components are proven 
risk factors for early blood vessel atherosclerosis and 
thrombosis [1], and individuals with MetSy have a three 
times greater risk to develop cardiovascular complica-
tions compared to those who do not have the syndrome 
[1,2]. Further, adult individuals with MetSy are exposed 
to a five-time greater risk of type 2 diabetes mellitus [3]. 
There are several definitions of MetSy proposed by 
various associations, such as World Health Organization 
(WHO), International Diabetes Federation (IDF), 
American Heart Association and National Heart, Lung 
and Blood Institute (AHA/NHLBI), National Choles-
terol Education Program, Third Adult Treatment Panel 
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(NECP/ATP III), and European Group for the Study of 
Insulin Resistance (EGIR). The definition by the expert 
team of the Third Panel of the National Cholesterol Ed-
ucation Program is based on the presence of three of the 
following five criteria: abdominal obesity, hypertriglyc-
eridemia, low HDL cholesterol, elevated blood pressure 
and hyperglycemia [4]. The prevalence of MetSy varies 
considerably depending on the criteria used to diagnose 
the condition. 
In patients without manifest cardiovascular disease, 
the thickness of the intimal medial complex (IMC) and 
ankle-brachial (pressure) index (ABI) represent non-
invasive surrogate markers of atherosclerosis associated 
with an increased risk for cardiovascular morbidity and 
mortality [5]. The literature data suggest a clear associ-
ation between cardiovascular risk factors and intimal 
medial thickness, as well as between intimal medial 
thickness and presence of clinical manifestations of cor-
onary disease [68]. It has been shown that intimal me-
dial thickness of the carotid arteries directly correlates 
with the involvement of cerebral, peripheral, and coro-
nary vascular bed by the process of atherosclerosis [6]. 
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Aim of the paper 
Our aim in this paper was to establish the prevalence of 
metabolic syndrome in patients with arterial hyperten-
sion (AH), as well as its impact on asymptomatic ca-
rotid atherosclerosis. 
Methods 
The study involved 391 examinees divided into two 
groups. The study group consisted of the patients with 
arterial hypertension (n=342; average age, 66.56 ± 
09.52; with 51% of women). In all the patients the pres-
ence of cardiovascular risk factors was established, car-
diovascular risk score was determined (SCORE risk), 
laboratory analyses were performed, as well as anthro-
pomentric measurements and color Doppler sonography 
of the great blood vessels of the neck. 
Analysis of the risk factors 
Based on the patient history and relevant medical records, 
the presence of both modifiable and unmodifiable risk 
factors for cardiovascular diseases was analyzed: AH, 
hyperlipidemia, smoking, diabetes, obesity, gender and 
age. Hypertension was defined based on the anamnestic 
data, medical records, measured systolic blood pressure 
values of over 140 mmHg and diastolic blood pressure of 
over 90 mmHg, or use of antihypertensive medications. 
The examinees with total cholesterol values of over 
5.0 mmol/L and/or triglycerides of over 1.7 mmol/L who 
were taking hypolipemic therapy were considered to be 
hyperlipidemic. The presence of diabetes was confirmed 
based on patient history information, available medical 
records, measured fasting glucose values of over 
5.6 mmol/L, or use of oral hypoglycemic medication or 
insulin therapy. The examinees with body mass index 
(BMI) ≥30 kg/m² were considered to be obese. An 
interactive electronic version of the SCORE risk charts 
from the European Society of Cardiology guidelines on 
CVD prevention (prepared by the Third Joint Working 
Group of the European Association of Preventive 
Cardiology – Heartscore) was used to assess the risk of 
fatal cardiovascular events in our examinees.  
Metabolic syndrome was diagnosed in accordance 
with the NECP/ATP III metabolic syndrome diagnostic 
criteria (The National Cholesterol Education Program, 
Adult Treatment Panel). 
Laboratory analyses 
General laboratory analyses were done in all the exami-
nees. Values of the following laboratory parameters 
were measured: total cholesterol, HDL and LDL cho-
lesterol fractions, triglycerides, creatinine, serum uric 
acid (employing standard laboratory methodology and 
using a Humastar 600 biochemical analyzer). Creatinine 
clearance was determined using the Cockcroft-Gault 
formula. 
Anthropometric measurements 
Anthropometric measurements involving body weight, 
body height, waist and hip circumference measurements 
were done in all examinees in order to get an insight 
into their nutritional status. The measurements were 
performed with light clothes and without any footwear. 
Body mass index (BMI) was determined using the fol-
lowing formula: body weight in kg/body height in m
2
. 
Color Doppler sonography (CDS)  
of the great blood vessels in the neck 
Color Doppler sonography of the great blood vessels in 
neck was done in all our examinees using the ultrasound 
scanner system EsaoteBiomedica, My Lab60 Xvision, 
with a multifrequency linear probe of 413 MHz. In-
traluminal lesions were determined using B-mode im-
aging and defined as changes in the form of IMC thick-
ening and appearance of plaques as focal intimal thick-
enings. IMC thickness was measured in the posterior 
wall of the common carotid artery 2 cm away from the 
top of the bifurcation, in the region without any focal 
changes. Longitudinal images of the common carotid 
artery and its branches (internal and external carotid 
artery) were analyzed bilaterally, determining the diam-
eter of stenosis and analyzing plaque properties. Inter-
pretations were based on the combination of B-mode, 
i.e. real-time tissue imaging, and Doppler spectral 
analysis. 
Statistical data processing 
The following statistical parameters were presented in 
the description: arithmetic mean (Xsr), standard devia-
tion (SD), absolute value and percentage (%) of attribu-
tive properties. Comparison of the mean values of nu-
merical properties between the two groups of examinees 
was done using the Student’s t-test. Linear regression 
analysis (by Spearman) was used to evaluate the associ-
ation of the factors of interest. The factors demonstrat-
ing a considerable impact on dependent variables in 
univariate analysis were included in multivariate models 
as independent variables. Statistical data processing was 
done using the SPSS software, 17.0 version. In all the 
analyses, the assessment error of 0.05 or 5% was taken 
as the cut-off of statistical significance. 
Results 
The patients with hypertension were divided into two 
groups by the presence of MetSy. Metabolic syndrome 
was confirmed in 198 patients and these comprised 
group I, while 144 examinees were without MetSy and 
these comprised group II. There was no age difference 
between the examinees with and those without MetSy. 
Those with MetSy had a greater average number of risk 
factors for cardiovascular diseases (CVD), a higher CV 
risk score – SCORE, and higher body mass index 
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(p<0.0001), and in this group of patients, diabetes, hy-
perlipidemia and obesity were more common (p <0. 0001), 
(Table 1). 
Table 1 Comparison of characteristics of the groups of 
examinees with and without metabolic syndrome 
Characteristic I group 
n=198 
II group 
n=144 
p value 
Age (in years) 66.80±9.76 66.24±9.17 n.s. 
Average number of 
risk factors  
2.69±0.82 1.85±0.58 0.0001 
SCORE risk  5.52±3.13 4.42±2.68 0.001 
Number of MetSy 
components  
3.47±0.70 1.76±0.45 0.0001 
Hyperlipidemia (%) 162 (81.2) 91 (63) 0.0001 
Diabetes mellitus (%) 59 (30) 3 (2.1) 0.0001 
Smoking ( %) 26 (13) 18 (12.5) n.s. 
Obesity (%) 110 (55.5) 14 (9.7) 0.0001 
BMI (kg/m2) 30.31±4.50 25.71±3.03 0.0001 
n.s. – no statistically significant difference between the two groups 
Examinees from the group I (with MetSy) had 
higher values of fasting glucose in the serum, higher 
levels of triglycerides and uric acid (p<0.0001), and 
lower values of HDL cholesterol fraction (Table 2).  
Table 2 Overview of laboratory analyses performed  
in the studied groups 
Characteristic 
 
I group 
n=198 
II group 
N=144 
p value 
Glycemia 
(mmol/L) 
6.25±1.98 5.47± 1.24 0.0001 
Cholesterol 
(mmol/L) 
5.52±1.33 5.71± 1.15 0.14 
LDL-cholesterol 
(mmol/L) 
3.53±1.28 3.65± 0.98 0.32 
HDL-cholesterol 
(mmol/L) 
1.12±0.27 1.36± 0.35 0.0001 
Triglycerides 
(mmol/L) 
2.35±1.51 1.42± 1.05 0.0001 
Uric acid 
(µmol/L) 
348.17±92.16 302.89±80.86 0.0001 
Creatinine 
(µmol/L) 
86.86±22.81 82.11±22.01 0.05 
Creatinine 
clearance (ml/min) 
76.57±20.55 84.54±28.37 0.0001 
Analysis of color Doppler ultrasound  
of the great blood vessels in the neck 
The thickness of the carotid IMC was significantly 
greater in the group with MetSy compared to those 
without the condition (p<0.0001), and 51% of exami-
nees had IMC thickness of ≥0.90. Those with MetSy 
more commonly had one or more carotid plaques 
(p=0.03), a greater average number of plaques (p=0.01) 
and a higher percentage of stenosis (p=0.01) compared 
to group II examinees (Table 3). 
Table 3 Color Doppler sonography of the great blood 
vessels in the neck in the studied groups 
Characteristic 
 
I group 
n=198 
II group 
n=144 
p value 
Thickness of the carotid 
IMC (mm) 
0.91±0.21 0.81±0.17 <0.0001 
Increased IMC 
thickness, n(%) 
101 (51) 47 (32.6) <0.001 
Presence of carotid 
plaques, n (%) 
142 (71) 88 (61) 0.03 
Average number of 
plaques 
1.62±1.35 1.27±1.20 0.01 
Average percentage of 
stenosis 
41.12±12.02 37.54±9.01 0.01 
Analyzing the carotid plaque characteristics, it was 
found that in the MetSy group plaques were most com-
monly fibrocalcified (29%), then fibrous (22%) and 
calcified (19%), and in the group without MetSy fibrous 
plaques were most prevalent (28%) (Table 4). 
Table 4 Carotid plaque characteristics  
in the studied groups 
Plaque characteristics,  
n (%) 
I group -  
MetSy 
II group -  
without MetSy 
Lipid  0  (0)  0 (0) 
Fibrolipid  2 (1)  3 (2.1) 
Fibrous  44  (22)  40  (28) 
Fibrocalcified  57  (29)  31  (21.5) 
Calcified  38  (19)  14  (9.7) 
As the most significant factors associated with early 
carotid atherosclerosis, multivariant regression analysis 
singled out the following (for the model R=0.512. 
R
2
=0.262. adjusted R
2
=0.255. standard error of the es-
timate = 0.174; p<0.0001): age (coefficiant β=0.331. 
p<0.0001), number of MetSy components (coefficient 
β=0.158. p=0.002), and serum level of uric acid (coeffi-
cient β=0.284; p<0.0001). 
Discussion 
Disorders of lipid and glucose metabolism, obesity and 
AH are defined as risk factors for cardiovascular dis-
eases, and these are at the same time the components of 
MetSy [1]. The prevalence of MetSy has been on the 
rise worldwide, but it is difficult to establish the preva-
lence more precisely due to different criteria used to 
define the condition. The INTERHEART study, per-
formed in 52 countries throughout the world, demon-
strated the prevalence of MetSy to be about 26% [9]. 
According to the data of the National Health and Ex-
amination Survey, the prevalence of MetSy in the 
United States of America changes with age; in men be-
low 40 years of age it is 20%, and in women of the same 
age it is 16%, while the prevalence of the condition in 
individuals of either gender aged over 60 years even 
exceeds 50% [10]. 
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In our examinees with AH, the prevalence of MetSy 
was significantly higher compared to controls, as well 
as the average number of present MetSy components. 
Those with AH and MetSy had a greater average num-
ber of risk factors for cardiovascular diseases, a higher 
CV risk score – SCORE, higher BMI, and diabetes, hy-
perlipidemia and obesity were more common in these 
individuals (Table 1). 
In the PIUMA study in Umbria, Italy, 1.742 exami-
nees without any manifest CV disease were prospectively 
observed for 10.5 years on the average; MetSy was 
established in 34% of them. Those with MetSy were 
older, and with longer history of AH and higher systolic 
blood pressure values. It was shown that MetSy was an 
independent predictor of future cardiovascular diseases in 
individuals of either gender with essential AH, and this 
prognostic effect of MetSy was not dependent on the 
traditional cardiovascular factors of risk, including left 
ventricular hypertrophy and ambulatory blood pressure 
measurement [11]. In the PIUMA study, the prevalence 
of diabetes was 14% [11], while in our examinees with 
MetSy the prevalence of diabetes was 30%, while in 
those without MetSy it was 2.1% (Table 1). The study by 
Marjani et al. showed a rather high prevalence of MetSy 
in patients with type 2 diabetes, with the percentage being 
higher in women (53.27%) than in men (48.71%) [12]. 
The prevalence of hyperlipidemia in our examinees 
was rather high – 81.2% in the first, and 63% in the se-
cond group. Laboratory analyses showed higher values 
of fasting glucose in the serum in patients with MetSy, 
higher triglyceride and uric acid levels, and lower val-
ues of HDL cholesterol fraction. There were no differ-
ences in the values of total and LDL cholesterol, proba-
bly due to the fact that the examinees with previously 
diagnosed hypercholesterolemia were treated with hy-
polipemic agents and/or employed non-pharmacological 
treatment measures. In individuals with MetSy, the so 
called atherogenic dyslipidemia predominates, charac-
terized by increased triglycerides and decreased HDL 
cholesterol, while LDL may be normal or only slightly 
elevated. Triglycerides play a significant role in the pro-
cesses of atherogenesis and thrombogenesis; in a meta-
analysis involving 101 prospective studies with 302.430 
examinees, it has been confirmed that elevated triglyc-
erides are an important factor associated with the devel-
opment of coronary heart disease [13]. 
The studies undertaken in Greece and the USA have 
shown that the prevalence of metabolic syndrome is 
similar in both genders [14]. On the other hand, there 
have been studies indicating a higher prevalence of 
MetSy in women or in men [15]. In our study, women 
more commonly had MetSy (59.6%). Deibert et al. 
demonstrated a prevalence of MetSy in postmenopausal 
women of 36.1% [16]. Furthermore, there have been 
studies suggesting that the differences in MetSy preva-
lence may be influenced by genetic factors and ethnicity 
as well [17]. 
Cardiovascular risk in individuals with MetSy is the 
product of different combinations of the components of 
the syndrome, which are not at all uniform. Each of the 
components is an independent risk factor for CVD and 
their synergistic action additionally increases the risk. 
Cardiovascular mortality is increased with an increasing 
number of MetSy components [18]. The results of mul-
tivariate regression analysis in our study singled out the 
number of MetSy components as one of the most im-
portant factors associated with atherosclerosis of the 
carotid arteries. 
Kuopio Ischaemic Heart Disease Risk Factor Study 
(KIHD) observed for 11.6 years on the average 1.209 
seemingly healthy men aged 42 to 60 years, where it 
was shown that CVD fatalities were 2.94.2 times more 
common in the presence of MetSy [19]. Among the pa-
tients of more advanced age (7079 years), the presence 
of MetSy was associated with a higher prevalence of 
coronary events, myocardial infarction, heart failure and 
hospitalizations regardless of the cause in the Health, 
Aging and Body Composition Study (HealthABC study) 
[20]. In the Medicine, Angioplasty or Surgery Study 
(MASS II), the patients with stable coronary disease 
were followed up for two years; those with MetSy had 
poorer CV outcomes and 2.5 times higher mortality 
independent of the factors of age, gender, smoking, 
LDL cholesterol and number of involved coronary 
blood vessels. The mortality of patients with MetSy was 
10.6% after two years, compared to 5.2% in those with-
out MetSy [21]. 
The current European guidelines for CVD preven-
tion in clinical practice, similarly to their predecessors, 
recommend the use of the SCORE system to assess the 
risk in asymptomatic patients since it has been based on 
a large representative European cohort [22]. In all the 
patients involved in our study SCORE was determined, 
and the obtained results demonstrated statistically sig-
nificantly higher SCORE values in those with AH and 
MetSy (Table 1). The results such as these could be in 
part expected, since the SCORE system was based on 
the presence or absence of some of the MetSy compo-
nents. Non-invasive imaging methods are able to iden-
tify asymptomatic atherosclerosis in various arterial 
areas and therefore supplement the assessment of risk. 
A special significance of these approaches lies in the 
detection of changes in their subclinical phase in indi-
viduals at high risk for the development of cardiovas-
cular diseases, so that the measures of prevention and 
appropriate treatments could be timely introduced. 
IMC thickness in the common carotid arteries repre-
sents a solid indicator of early atherosclerosis [23], and 
a number of studies, including the Multi-Ethnic Study 
of Atherosclerosis (MESA) in asymptomatic patients, 
have shown that the IMC thickness exceeding 75 per-
centiles for age, gender and race is associated with the 
risk for myocardial infarction, stroke and cardiovascular 
mortality independently of other conventional risk fac-
tors [24]. The association of MetSy with subclinical 
atherosclerosis was the subject of a number of studies 
employing non-invasive imaging techniques. In the 
study by Holewijn et al., involving 1.517 individuals 
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with MetSy aged 50 to 70 years, a significant association 
was found between asymptomatic atherosclerosis and 
MetSy, regardless of the employed imaging method [25]. 
IMC thickness of the carotid arteries in our exami-
nees was significantly greater in the group with MetSy 
compared to those without MetSy (Table 3), where in-
creased IMC thickness (≥ 0.90) was found in 51% of 
examinees with MetSy. Those with MetSy more com-
monly had one or more carotid plaques, a greater aver-
age number of plaques and percentage of stenosis (Ta-
ble 3). Similar results were published by Olijhoek et al. 
in the Netherlands, examining the association of MetSy 
with changes in the coronary, cerebral and peripheral 
arteries. The prevalence of MetSy in that study was 45%; 
their patients had greater IMC thickness, a lower ankle-
brachial index, and more prevalent microalbuminemia 
compared to those without MetSy. Furthermore, they 
demonstrated that with an increasing number of MetSy 
components, IMC thickness increased as well [26]. 
In our analysis of the characteristics of carotid 
plaques, we found that in our examinees with MetSy 
plaques were most commonly fibrocalcified, then fi-
brous and lastly calcified, while in those without MetSy 
fibrous plaques predominated (Table 4). However, it 
was interesting to note that lipid plaques were not pre-
sent in any of the 342 patients with AH, with or without 
MetSy. The presence of soft lipid and fibrolipid plaques 
has been usually associated with the risk for neurologi-
cal complications (transitory ischemic attacks, reversi-
ble ischemic deficits or cerebrovascular insults) due to 
an increased embolic potential of these plaques [27]. On 
the other hand, the presence of carotid plaques suggests 
that plaques in the coronary arteries may be present as 
well. The presence of less echo-lucent plaques in stable 
coronary patients has been able to predict acute coro-
nary syndrome in the future, regardless of the presence 
of other factors of risk [28]. Khoury et al. have demon-
strated that patients with multi-vessel coronary disease 
had a higher carotid plaque score compared to those 
with single-vessel coronary disease or normal coronary 
blood vessels [29]. Recent analyses have shown that the 
presence plaques in the carotid arteries has a greater 
predictive significance regarding future CV events, 
compared to IMC thickness [30]. 
Conclusion 
Arterial hypertension is commonly associated with met-
abolic disorders, especially with insulin resistance and 
MetSy. In our study, we demonstrated that in patients 
with AH the prevalence of MetSy was significantly 
higher than in healthy individuals. Patients with AH and 
MetSy had a greater average number of risk factors for 
cardiovascular diseases, higher score of CV risk – 
SCORE, higher body mass index, diabetes was more 
often present, as well as hyperlipidemia and obesity. 
The results indicated the presence of a significant asso-
ciation between MetSy and its components and athero-
sclerotic changes in the carotid arteries. 
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